Document Detail

Growth inhibition and induction of apoptosis of colon cancer cell lines by applying marine phospholipid.
MedLine Citation:
PMID:  19116882     Owner:  NLM     Status:  MEDLINE    
Polyunsaturated fatty acids (PUFAs) exhibit beneficial biological functions in carcinogenic processes. We examined the effects of PUFAs in the acid and phospholipid forms on three colon cancer cell lines (HT-29, Caco-2, and DLD-1). Docosahexaenoic acid (DHA) and eicosapentaenoic (EPA) in both acid and phospholipid forms showed growth inhibition effects on experimental colon cancer cell lines. But these PUFAs had the strongest growth-inhibitory effect on HT-29 than Caco-2 and DLD-1. Combined application of PUFAs and sodium butyrate (NaBt) increased the growth inhibition. Growth inhibition was apparently caused by increased lipid peroxidation. DHA or EPA in combination with NaBt significantly increased caspase-3 activity compared to control. DHA and DHA-rich phosphatidylcholine decreased Bcl-2 level in HT-29 and Caco-2 cells.
Zakir Hossain; Masashi Hosokawa; Koretaro Takahashi
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Nutrition and cancer     Volume:  61     ISSN:  1532-7914     ISO Abbreviation:  Nutr Cancer     Publication Date:  2009  
Date Detail:
Created Date:  2008-12-31     Completed Date:  2009-04-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7905040     Medline TA:  Nutr Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  123-30     Citation Subset:  IM    
Division of Applied Biosciences, Graduate School of Agriculture, Kyoto University, Kyoto, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antioxidants / pharmacology
Apoptosis / drug effects*
Arachidonic Acid / chemistry
Asterias / chemistry
Butylated Hydroxytoluene / pharmacology
Butyrates / metabolism,  pharmacology
Caco-2 Cells
Caspase 3 / metabolism
Cell Line, Tumor
Cell Survival / drug effects
Colonic Neoplasms / drug therapy*,  metabolism,  pathology
Cyclooxygenase Inhibitors / pharmacology
Decapodiformes / chemistry
Fatty Acids, Unsaturated / metabolism,  pharmacology*
HT29 Cells
Indomethacin / pharmacology
Lipid Peroxidation* / drug effects,  physiology
Phospholipids / metabolism,  pharmacology*
Reg. No./Substance:
0/Antioxidants; 0/Butyrates; 0/Cyclooxygenase Inhibitors; 0/Fatty Acids, Unsaturated; 0/Phospholipids; 128-37-0/Butylated Hydroxytoluene; 506-32-1/Arachidonic Acid; 53-86-1/Indomethacin; EC 3.4.22.-/Caspase 3

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Conjugated linoleic acid (CLA) inhibits expression of the Spot 14 (THRSP) and fatty acid synthase ge...
Next Document:  Magnesium deficiency affects mammary epithelial cell proliferation: involvement of oxidative stress.